As mentioned above, the presence of SLFN11 was found to be associated with sensitivity to DDA and PARPi across a variety cancer cell lines and patient-derived xenografts, including small cell lung cancer, colorectal cancer, sarcoma, gastric cancer, mesothelioma, and ovarian cancer. This evidence concerns the gene SLFN11 and ovarian carcinoma.